Pathogenetic basis of modern approaches to the therapy of sleep disorders in the clinic of depression
- 23 April 2024
- journal article
- review article
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (4) , 69-74
Abstract
Epidemiological studies indicate that about 35% of the world’s population periodically suffer from insomnia. Many authors in their studies note sleep disturbances in the clinic of both somatic and mental disorders, often considering sleep disturbances as one of the predictors of these diseases. In psychiatric practice, sleep disorders are most often described in the clinic of depression, which is determined by the general pathophysiological mechanisms of their development due to disruption of the activity of the main neurotransmitter systems of the brain. The results of clinical studies show that the drug of choice in the treatment of sleep disorders in the depression clinic is the antidepressant Mirtazapine, which has a unique profile of pharmacological activity. According to international recommendations, Mirtazapine is a first-line drug in the treatment of anxiety and depressive disorders with sleep disorders and sexual dysfunction caused by taking other antidepressants.Keywords
This publication has 46 references indexed in Scilit:
- Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide StudyJAMA Psychiatry, 2023
- Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysisJournal of Affective Disorders, 2022
- Sleep disorders and cancer: State of the art and future perspectivesSleep Medicine Reviews, 2021
- The psychological impact of quarantine and how to reduce it: rapid review of the evidenceThe Lancet, 2020
- Pharmacological interventions for treatment-resistant depression in adultsCochrane Database of Systematic Reviews, 2019
- Sexual Dysfunction associated with Second-Generation Antidepressants in Patients with Major Depressive Disorder: Results from a Systematic Review with Network Meta-AnalysisDrug Safety, 2013
- Mirtazapine versus other antidepressive agents for depressionCochrane Database of Systematic Reviews, 2011
- Circadian rhythm disturbances in depressionHuman Psychopharmacology: Clinical and Experimental, 2008
- The antinociceptive effect of mirtazapine in mice is mediated through serotonergic, noradrenergic and opioid mechanismsBrain Research Bulletin, 2002
- A double-blind, placebo-controlled study of antidepressant augementation with mirtazapineBiological Psychiatry, 2002